Business Description
Mereo BioPharma Group PLC
ISIN : US5894921072
Share Class Description:
LTS:0A9G: ADRDescription
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.05 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 11.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 60.4 | |||||
| 3-Year EPS without NRI Growth Rate | 39.9 | |||||
| 3-Year FCF Growth Rate | 34.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 87.02 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.99 | |||||
| 9-Day RSI | 36.25 | |||||
| 14-Day RSI | 38.97 | |||||
| 6-1 Month Momentum % | -0.4 | |||||
| 12-1 Month Momentum % | 76.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.1 | |||||
| Quick Ratio | 6.1 | |||||
| Cash Ratio | 5.67 | |||||
| Days Sales Outstanding | 3633.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.5 | |||||
| Shareholder Yield % | 1.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 127.3 | |||||
| Operating Margin % | -3806.5 | |||||
| Net Margin % | -4531.6 | |||||
| FCF Margin % | -3090.2 | |||||
| ROE % | -74.12 | |||||
| ROA % | -58.98 | |||||
| ROIC % | -444.47 | |||||
| ROC (Joel Greenblatt) % | -3141.62 | |||||
| ROCE % | -69.22 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 464.3 | |||||
| PB Ratio | 6.93 | |||||
| Price-to-Tangible-Book | 8.24 | |||||
| EV-to-EBIT | -11.62 | |||||
| EV-to-EBITDA | -11.92 | |||||
| EV-to-Revenue | 517.26 | |||||
| EV-to-FCF | -14.63 | |||||
| Price-to-Net-Current-Asset-Value | 8.24 | |||||
| Price-to-Net-Cash | 9.02 | |||||
| Earnings Yield (Greenblatt) % | -8.6 | |||||
| FCF Yield % | -5.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mereo BioPharma Group PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1 | ||
| EPS (TTM) ($) | -0.3 | ||
| Beta | -2.35 | ||
| Volatility % | 73.58 | ||
| 14-Day RSI | 38.97 | ||
| 14-Day ATR ($) | 0.190029 | ||
| 20-Day SMA ($) | 3.569515 | ||
| 12-1 Month Momentum % | 76.1 | ||
| 52-Week Range ($) | 2.138 - 5.009 | ||
| Shares Outstanding (Mil) | 155.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mereo BioPharma Group PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mereo BioPharma Group PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mereo BioPharma Group PLC Frequently Asked Questions
What is Mereo BioPharma Group PLC(LTS:0A9G)'s stock price today?
The current price of LTS:0A9G is $3.79. The 52 week high of LTS:0A9G is $5.01 and 52 week low is $2.14.
When is next earnings date of Mereo BioPharma Group PLC(LTS:0A9G)?
The next earnings date of Mereo BioPharma Group PLC(LTS:0A9G) is 2025-03-27 Est..
Does Mereo BioPharma Group PLC(LTS:0A9G) pay dividends? If so, how much?
Mereo BioPharma Group PLC(LTS:0A9G) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers